Found: 2
Select item for more details and to access through your institution.
Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trials.
- Published in:
- Signal Transduction & Targeted Therapy, 2021, v. 6, n. 1, p. 1, doi. 10.1038/s41392-021-00692-3
- By:
- Publication type:
- Article
Effects of Prior Influenza Exposure on Immunogenicity of Influenza Vaccine.
- Published in:
- Open Forum Infectious Diseases, 2020, v. 7, n. 8, p. 1, doi. 10.1093/ofid/ofaa181
- By:
- Publication type:
- Article